Abstract
Nature 535, 511–516 (2016); doi:10.1038/nature18634 In the interests of transparency, in this Article we wish to amend the competing financial interests statement to read: “Tuebingen University has filed a provisional patent application that covers the compound lugdunin and derivatives thereof, as well as the application of lugdunin-producing bacteria for the prevention of bacterial infections (European patent application number EP 15 160 285.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have